Lee Brodie is Digital Producer for Mad Money with Jim Cramer. Past credits include "Trading Spaces" and "Entertainment Tonight." He has also produced shows for History, MSNBC, NBC Productions, PBS and more. He received a 2007 Daytime Emmy award for the A&E documentary "A Question of Life or Meth." Brodie also received an Emmy award for his coverage of the New York theater scene in "Live from Broadway with Pat Collins." His first job in media was also with NBC, as a page.
When every asset class in the market appears to be falling, we bring you trades that go their own way. These are the Renegade trades. Specifically, these are the assets that are not correlated to the S&P 500. Merrill Lynch in a note today said that many traditional instruments that used to go their own way, such as wine and art, are more highly correlated to the stock market so that leaves investors searching.
The greatest demographic shift of our time is underway. The baby boom generation is getting older. And as their interests and needs change with age, big money will follow. Only Fast Money takes you inside companies that will profit as the boomers age.
"Asia Trade Looking Bleak as Investors Flee Japan, Malaysia and China." Asia's financial markets began the week with more selling. Japan's Nikkei dropped the most in 9 months today on concerns that a stronger yen will hurt sales of Japanese exporters such as Toyota.
"Mortgage Meltdown or Media Hysteria, You Decide" From reading the newspapers, you’d think there was a virtual mortgage crisis in America. But look again! While home loans to people with poor credit (the so called sub-prime market) has grown as a business, it’s still a relatively small part of the total mortgage pie, less than 15% by most accounts.
"Bears Win Monday Tussle; Stocks' Worst Slide in Four Years Continues" The stock market climbed back from a morning loss only to lose it in the final hour and close at its low for the day. The bears latched onto a report about the service economy as the latest piece of evidence to show that economic growth is slowing more than expected.
John from Florida asked about Amgen. This stock is hanging around a 52 week low and was down 4% yesterday on the news that the SEC is probing their anemia drug Aranesp. Given the unstable market conditions we have, I am wondering if 4% was an overreaction and if AMGN is a buy here?
The bloodletting continued today as the Dow Jones Industrial Average plunged another 120 points. When all was said and done, the blue-chip meausure lost more than 4% on the week. The scary part is that no one is exactly sure why. In such an uncertain and potentially treacherous environment, what's your next move?
Grab the latest CNBC gear from the NBCUniversal Store!
Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.
You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.